Page 18 - Noble-Virtual-Healthcare-2024

Health Care
Date April 15, 2024 Health Care
52wk High $1.71
52wk Low $0.60 Citius Pharmaceuticals, Inc. CTXR $0.77
11 Commerce Drive
Cranford, NJ 07016

(USD - in millions) citiuspharma.com
Market Cap 125.3
Enterprise 106.0
Basic Shares Out. 159.09 COMPANY OVERVIEW
Float 146.77
Institutional Holdings 16.97% Detailed Analysis:
Short Interest 12.43 Citius Pharma is a late-stage biopharmaceutical company dedicated to
Avg. 90-Day Volume 0.75 the development and commercialization of first-in-class critical care
products. The Company's diversified pipeline includes two late-stage
product candidates. At the end of 2023, Citius completed enrollment in
a Phase 3 pivotal superiority trial of Mino-Lok®, an antibiotic lock
EPS Data solution to salvage catheters in patients with catheter-related
bloodstream infections. Citius resubmitted the Biologics License
2021 2022 2023 Application for LYMPHIR, a novel IL-2R immunotherapy for an initial
CQ1 (0.04) (0.05) (0.07) indication in cutaneous T-cell lymphoma, in early 2024, and announced
CQ2 (0.05) (0.06) (0.06) plans to form Citius Oncology, a standalone publicly traded company
with LYMPHIR as its primary asset. LYMPHIR received orphan drug
CQ3 (0.03) (0.05) (0.07) designation by the FDA for the treatment of CTCL and PTCL.
CQ4 (0.06) N/A N/A
CY (0.18) (0.23) (0.22) Source: Channelchek/QuoteMedia

Long-Term EPS Estimate N/A
Price/Book (mrq) 0.53
ROE (ttm) -40.97
Debt-to-Total Cap. (mrq) 0.50
Fiscal Year End 30-Sep
11 Commerce Cranford NJ 07016

Key Executives
CEO: Mazur, Leonard
CFO: Bartushak, Jaime
COO: Talarico, Gary
IR: Allen, Ilanit
Noble Capital Markets, Inc.
Source: Capital IQ, Noble Financial estimates, company filings
Noble Senior Analyst 561-994-1191 noblecapitalmarkets.com
Robert Leboyer MEMBERS: FINRA, SIPC, MSRB
rleboyer@noblelsp.com Following the conference, complete video library of presentations will be
available at: channelchek.com | nobleconference.com
(212) 896-4625

Refer to the back of the book for disclosures